The 5-HT 3 receptor is a prototypical member of the Cys-loop ligand-gated ion channel (LGIC) superfamily and an established therapeutic target. In addition to activation via the orthosteric site, receptor function can be modulated by allosteric ligands. We have investigated the pharmacological action of Cl-indole upon the 5-HT 3 A receptor and identified that this positive allosteric modulator possesses a novel mechanism of action for LGICs.
Introduction
The 5-HT 3 receptor is an excitatory ligand-gated ion channel (LGIC) of the Cys-loop family that includes the nicotinic ACh receptors (nAChR), glycine and GABA A receptors, and Zn 2+ -activated receptors (Barnes et al., 2009; daCosta and Baenziger, 2013) . Members of this LGIC family share a common pentameric structure, an observation recently confirmed by the publication of the X-ray structure of the mouse 5-HT 3 A receptor (Hassaine et al., 2014) . Each subunit of the 5-HT 3 receptor is composed of an extracellular N-terminal domain, four transmembrane domains and a short extracellular C-terminal domain. The orthosteric binding site is located at the interface between two adjacent N-terminal domains (daCosta and Baenziger, 2013) .
Five human 5-HT 3 receptor subunits have been identified (5-HT3A to 5-HT3E) (Karnovsky et al., 2003; Niesler et al., 2003) . The native receptor can exist as a simple homopentamer of 5-HT3A subunits or heteropentamers containing the 5-HT3A subunit and at least one other of the 5-HT3B to E subunits (Niesler, 2011) . The pentameric structure gives rise to a potential for five ligand binding sites, but recent evidence suggests that just two or three sites are occupied for maximal activation of the channel (Corradi et al., 2009) . Studies using heteromeric 5-HT 3 AB receptors suggest that orthosteric binding sites are only formed between adjacent 5-HT3A subunits (Lochner and Lummis, 2010; Thompson et al., 2011) .
As well as orthosteric agonism, allosteric modulation of the 5-HT 3 receptor has been reported by compounds as diverse as alcohols (Downie et al., 1995; Bentley and Barnes, 1998; Stevens et al., 2005) , cannabinoids (Barann et al., 2002) , indole derivatives (Parker et al., 1996; Van Hooft et al., 1997; Newman et al., 2013) , terpenes (Lansdell et al., 2015; Ziemba et al., 2015) , benzamides (Jørgensen et al., 2011) and the class of novel negative allosteric modulators typified by PU02 (Trattnig et al., 2012) . A number of these modulators appear to have their effect via a site (or sites) in the transmembrane domain [e.g. for the indole derivatives (Hu and Lovinger, 2008) ]. Allosteric agonism by phenolic monoterpenes has also been reported recently again via an allosteric transmembrane site (Lansdell et al., 2015) . An additional potential level of allosteric modulation has been demonstrated since mutation of the intracellular portal region of the receptor affected gating and co-operativity [e.g. (Kozuska et al., 2014) ]. This raises the possibility of receptor interactions with intracellular proteins leading to allosteric modulation of receptor function.
While the majority of these allosteric effects are mediated by discrete, non-orthosteric sites, it is becoming apparent that some indole derivatives have a more intriguing and mixed mode of action. In particular, they may have mixed effects depending on their concentration and structure. For instance, the non-selective positive allosteric modulator, 5-hydroxy-indole (5OHI) displays positive allosteric modulation via a transmembrane domain of mouse 5-HT 3 A receptors (Hu and Lovinger, 2008) , and can also display orthosteric agonism and allosteric inverse agonism at a spontaneously active mutated mouse 5-HT 3 A receptor. These differing actions were dependent only on concentration. The closely related molecule, 5-methoxy-indole displayed both allosteric agonism and orthosteric inverse agonism at the same receptor, again dependent on concentration (Hu, 2015) . Importantly, the presence of the orthosteric ligand was not required for these actions.
We have recently described a selective allosteric modulator of the 5-HT 3 receptor, 5-chloro-indole (Cl-indole; (Newman et al., 2013) . Our study suggested that Cl-indole slows the decay of 5-HT 3 A receptor currents and that it can reactivate desensitized 5-HT 3 A receptors in the continued presence of 5-HT (Newman et al., 2013) . In the light of the mixed modes of action described for indole derivatives, we undertook a study to further explore the mode of action of Cl-indole on the modulation of the 5-HT 3 receptor. We identified for the first time within the LGIC superfamily, an agoallosteric modulation in which both agonism and allosteric modulation require the presence of the orthosteric ligand.
Methods

Cell culture
HEK293 cells stably expressing the human 5-HT 3 A subunit [HEK293-5-HT 3 A cells (Brady et al., 2001)] or the heteromeric 5-HT 3 A/5-HT 3 B receptor [HEK293-5-HT 3 A/ 3 B cells (Dubin et al., 1999) ] were grown in DMEM, supplemented with 10% (v·v À1 ) FBS, 1% (v·v À1 ) penicillin/streptomycin (10 000 U·mL À1 penicillin and 10 mg·mL À1 streptomycin) and G418 (250 μg·mL À1 ) or G418 plus zeocin (250 μg·mL À1 each, HEK293-5-HT 3 A/ 3 B cells) and maintained at 37°C, 5% CO 2 , 95% air at 95% relative humidity. 
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Radioligand binding
Radioligand binding assays were performed similar to our previous studies (e.g. Monk et al., 2004) . Briefly, cells were homogenized (Polytron) and resuspended in Tris buffer (in mM; Tris 25, pH 7.4 adjusted with NaOH). Radioligand binding assays were performed in triplicate; binding tubes contained 500 μL of competing drug(s) or vehicle (Tris buffer), and 100 μL of [3H]-granisetron (~1 nM;~3 TBqmmol-1; Perkin-Elmer). An aliquot (100 μL) of the cell homogenate was added to initiate binding, which was allowed to proceed at room temperature for 60 min before termination by rapid filtration and washing with Tris buffer under vacuum through Whatman GF/B filters, followed by assay of the radioactivity remaining on the filters.
5-HT-binding protein
The A1B2D1 W 5-HT-binding protein was produced and binding experiments with the protein were performed exactly as described previously (Kesters et al., 2013) . Radioactivity was determined using a Top Count Scintillation and Luminescence reader (Packard).
Single cell electrophysiology
Approximately 18 h prior to electrophysiology assays, cells were seeded directly onto 13 mm diameter glass coverslips coated with poly-L-lysine and fibronectin, at a density of 2 × 10 4 cells per coverslip. Macroscopic currents were recorded in the whole-cell recording mode of the patch-clamp technique from HEK293-5-HT 3 A cells or HEK293-5-HT 3 A/ 3 B cells cultured on coverslips using an inverted microscope. Cells were superfused at~4 mL·min À1 with an extracellular solution (in mM; NaCl 140, KCl 2.8, CaCl 2 1.0, glucose 10, HEPES 10, pH 7.4 adjusted with NaOH). Patch electrodes were pulled from borosilicate glass (O.D. 1.2 mm, I.D. 0.69 mm; Harvard Apparatus, Edenbridge, UK) using a P-97 puller (Sutter, Novato, CA) and filled with intracellular solution consisting of (in mM) 135 CsCl, 2 MgCl 2 , 10 HEPES, 1 EGTA, 2 Mg-ATP and 0.3 Na-GTP; pH adjusted to 7.3 with KOH (os-molarity~285 mOsm). Patch electrodes typically had open tip resistances of 4-7 MΩ. Membrane currents were recorded using an Axopatch 200B amplifier (Molecular Devices, Wokingham, UK), low-pass Bessel filtered at 1 kHz (NL-125, Digitimer Ltd, Welwyn Garden City, UK) and digitised at 10 kHz by a digidata 1302 (Molecular Devices). Experiments were performed at room temperature with the cells voltageclamped at À60 mV. Agonist-evoked currents were elicited by pressure ejection (20-kPa; Picospritzer II; General Valve, Fairfield, NJ) of agonist (5-HT 1.0-10 μM) from modified patch pipettes placed 30 μm from the recorded cell.
Data and statistical analysis
Values are expressed as mean ± SEM. Curve fitting and data analysis were performed in Origin 8 (Silverdale Scientific, Stoke Mandeville, UK). Experimenters were not blinded to the experimental conditions. Experiments were randomised where appropriate (e.g. for the paired pulse experiments, interpulse interval was randomised using a latin square design). ANOVA with subsequent unpaired t-tests (with Bonferonni correction for multiple comparisons) were used to evaluate differences; a Shapiro-Wilk tested normality.
Post hoc tests were only conducted if F was <0.05; the variance of the data was homogeneous. Significance criterion was P < 0.05. Data and statistical analysis complied with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Results
Cl-indole modulates 5-HT-induced responses but is not an agonist
A brief application of Cl-indole (30 μM, 100 ms) did not evoke a current in HEK293 cells expressing the human 5-HT 3 A receptor ( Figure 1 ) whereas bath application of 5-HT (10 μM) produced a large inward current. As the 5-HT-induced current began to decay, a second brief application of Cl-indole (30 μM, 100 ms) reactivated the current (Figure 1 ). These data demonstrate the Cl-indole is not an agonist in its own right, but in the presence of 5-HT, it is capable of modulation of the 5-HT 3 A receptor. The reactivation of the current suggested that Cl-indole might act via an effect on either desensitization or resensitization of the receptor.
Cl-indole does not modulate 5-HT 3 A receptor desensitization
In order to establish if Cl-indole modulates receptor desensitization, we tested the effect of Cl-indole on the rate of receptor desensitization evoked by prolonged receptor activation. Twenty second applications of 5-HT (10 μM) produced large currents (1.53 ± 0.25 nA, n = 11) that displayed profound desensitization (12.4 ± 3.23% of peak; Figure 2Ai ). The current decay was best fit with a double exponential function, with time constants of 1.02 ± 0.09 s and 9.79 ± 1.09 s (Figure 2Bi and Bii). Superfusion of Cl-indole (10 μM) did not alter the amplitude of 5-HT induced currents (1.37 ± 0.27 nA, n = 11); nor did it alter the degree (13.9 ± 3.9% of peak) or rate (τ 1 1.22 ± 0.20 s,; τ 2 7.78 ± 0.41 s) of receptor desensitization (2). These data demonstrate that Cl-indole does not modulate 5-HT 3 A receptor desensitization.
Cl-indole does not modulate 5-HT 3 A receptor resensitization
We previously demonstrated that when 5-HT 3 A receptors were completely desensitized by prolonged application of 5-HT, subsequent application of Cl-indole generated an inward current indicative of Cl-indole being able to reactivate desensitized receptors (Newman et al., 2013 ) (see also Figure 1 ). We therefore tested whether Cl-indole could modulate receptor resensitization using a dual pulse protocol; a single prolonged application of 5-HT (10 μM, 20 s) induced receptor desensitization ( Figure 3A ). After removal of the 5-HT, a second test pulse of 5-HT (10 μM, 1 s) was applied with a delay between 5 s and 2 min. Recovery from desensitization was estimated by the fractional recovery of the current elicited by the second 5-HT pulse and was plotted against the inter-pulse interval. Cl-indole did not modulate the rate of receptor resensitization (control τ r = 18.4 ± 2.0 s; Cl-indole τ r 17.7 ± 3.1 s; n = 5, Figure 3B ).
Cl-indole induces tail currents
In the absence of Cl-indole, removal of 5-HT resulted in the evoked currents decaying back to the resting holding current level (see Figure 3A and 4A, black traces). In contrast, removal of 5-HT in the continued presence of Cl-indole resulted in a relatively large, slowly developing inward tail current, which peaked at 158.3 ± 30.1 pA (13.3 ± 1.8%) of the 5-HT-induced current amplitude ( Figure 4A , red trace; n = 13; see also Figure 3A , red trace). The rise time of the tail current was best fit by a single time constant (τ 2.77 ± 0.35 s), and the tail current decayed slowly back to baseline (time to reach 50% level 11.06 ± 1.7 s). The effect of Cl-indole on the presence of a tail current was completely reversed upon wash ( Figure 4A , grey trace). As the tail current arose immediately after the removal control conditions Cl-indole
Figure 2
Cl-indole does not modulate 5-HT 3 A receptor desensitization (Ai); Prolonged application of 5-HT (10 μM, 20 s) activated a large 5-HT 3 A receptor current that displayed pronounced desensitization under control conditions; single recording representative of 11 recordings. The magnitude and kinetics of desensitization of the current evoked by 10 μM 5-HT were unaffected by concomitant bath application of Cl-indole (10 μM).
(Aii) Normalizing 5-HT (10 μM) induced current to the peak response highlighted the lack of effect of Cl-indole on receptor desensitization.
(Bi and ii) The time constants of the current decay in the absence or presence of Cl-indole (10 μM). (Biii) Degree of receptor desensitization in the absence or presence of Cl-indole (10 μM). Data represent the mean ± SEM, n = 11.
of the 5-HT, we examined if the tail current amplitude was correlated with the current remaining at the end of the agonist application; we also used lower concentrations of 5-HT (1-3 and 1 μM) as these lower 5-HT concentrations evoked currents with reduced desensitization ( Figure 4B ). The tail current amplitude did not correlate with the amount of current remaining (Figure 4Bi , n = 27, ANOVA, P > 0.05). In contrast, the amplitude of the tail current correlated positively with the 5-HT 3 A receptor current density (Figure 4Bii , n = 13, ANOVA P < 0.05).
In order to further explore the origin of the tail current, we examined the current-voltage relationship of the tail current. Similar to the I/V curve for the 5-HT 3 A receptor current, the I/V curve for the tail current reversed at approximately zero mV ( Figure 5 ). These data suggest that the tail current arises from activation of 5-HT 3 A channels (see also Figure 7 ), and that channel opens in a manner consistent with orthosteric receptor activation.
The tail current recorded in the presence of Cl-indole was qualitatively similar to tail currents that arise following relief from open channel block (Rossokhin et al., 2014) . Given that 5-HT is known to induce channel block at concentrations above 5 μM (Corradi et al., 2009) , we explored further if Cl-indole could induce tail currents after application of lower concentrations of 5-HT. Cl-indole did not potentiate 3 μM 5-HT-induced currents (Control =0.73 ± 0.11 nA; Cl-indole =0.68 ± 0.17 nA; n = 6), yet the presence of Cl-indole induced a tail current upon removal of the lower concentration of 5-HT ( Figure 6 ). Following removal of 5-HT at 3 μM, the tail current peaked at 135 ± 29.8 pA (18.7 ± 3.3% of the agonist induced current; n = 6), with a similar decay time (8.54 ± 1.1 s). The rise time in the tail current (5.42 ± 0.78 s) following removal of 5-HT at 3 μM was significantly slower than for tail currents evoked following removal of 10 μM 5-HT ( Figure 6 ).
Cl-indole (10 μM) potentiated 1.0 μM 5-HT-induced currents (Control =149.0 ± 50.7 pA; Cl-indole =473.5 ± 146.0 pA; n = 9, P< 0.05) but not currents arising from higher concentrations of 5-HT. In the presence of Clindole (10 μM), tail currents were also observed following removal of 5-HT at 1 μM; the peak amplitude of the tail current was 197.5 ± 50.6 pA, the rise time was significantly slower (7.37 ± 0.81 s) and the decay time was unaltered (13.73 ± 1.0 s; n = 9; Figure 6 ). Although the peak amplitude of the tail current evoked by removal of 1 μM 5-HT did not significantly differ from those evident following removal of higher 5-HT concentrations, the Cl-indole-induced tail currents evoked following removal of 1 μM 5-HT were significantly larger relative to the 5-HT-induced peak current (108.2 ± 37.3%; n = 9).
Does Cl-indole function as an ago-allosteric modulator?
The homomeric 5-HT 3 A receptor has five potential orthosteric binding sites, but various studies have shown that even when fully activated only three molecules of 5-HT are bound per receptor leaving unbound orthosteric sites (Mott et al., 2001; Solt et al., 2007; Corradi et al., 2009) . Given the structural similarity between Cl-indole and the natural ligand 5-HT, we hypothesized that Cl-indole may function as an ago-allosteric modulator, a mode of action which has previously been described in members of the GPCR superfamily (Schwartz and Holst, 2006) . We tested this in two ways: firstly, we examined if the competitive antagonist, ondansetron, which interacts with the orthosteric site, could block the Cl-indole-induced tail current. Secondly, we examined if 5-HT could modulate the ability of Cl-indole to interact with the orthosteric site in radioligand binding studies.
In the continual presence of Cl-indole, ondansetron (10 μM) was applied via a second picospritz pipette 1 s prior to the withdrawal of the 5-HT. In the absence of ondansetron, tail current amplitude was 250 ± 18 pA, whereas effectively no tail current was observed in the presence of ondansetron (11 ± 3 pA; n = 5, Figure 7A ). In a parallel set of experiments, we tested the effect of ondansetron (10 μM) applied after Cryptic orthosteric modulation of 5-HT 3 A BJP development of the tail current. Ondansetron applied at the peak of the tail current immediately reduced the current back to baseline levels ( Figure 7B, n=5) . The duration of the tail current (in the order of seconds) would suggest that it is occurring without the presence of the orthosteric ligand (which would be washed away). As ondansetron competively binds at the orthosteric site (Duffy et al., 2012) , this strongly argues that Cl-indole interacts with the orthosteric site.
These data demonstrate that antagonism of the orthosteric site prevents Cl-indole-evoked tail currents.
We have previously demonstrated that Cl-indole (in the absence of 5-HT) at concentrations up to 100 μM does not compete with [ 3 H]-granisetron binding at the 5-HT 3 A receptor (Newman et al., 2013) , which was confirmed in the present study (Figure 8 ). However, in the presence of submaximal concentrations of 5-HT, Cl-indole competed for [ 3 H]-granisetron binding sites, with the affinity of Cl-indole increasing for the [ 3 H]-granisetron-labelled orthosteric site of the 5-HT 3 A receptor binding site with increasing concentrations of 5-HT ( Figure 8 , Table 1 ). In contrast, parallel experiments demonstrated that sub-maximal concentrations of 5-HT failed to modify the affinity of the partial agonist phenylbiguanide (Figure 8 , Table 1 ).
In complementary experiments, we tested the ability of Cl-indole to bind to the 5-HT binding protein. This protein, formed by mutation of the ACh binding protein, is able to bind 5-HT albeit with reduced affinity compared with the native 5-HT 3 receptor (Kesters et al., 2013) . At higher concentrations, Cl-indole competed with [ 3 H]-granisetron but did not show the same increase in affinity in the presence of 5-HT as for the homomeric receptor (Supporting Information Figure S1 ), which suggests the 5-HTBP does not fully replicate the interaction of Cl-indole with the h5-HT 3 A receptor.
Figure 4
Cl-indole evokes tail currents. (A) In control conditions, the current decayed back to baseline levels after removal of 5-HT. In contrast, removal of the agonist in the presence of Cl-indole induced a tail current with slow activation and deactivation kinetics. The presence of the tail current was completely reversible upon removal of Cl-indole; trace representative of 13 recordings. (B) Peak tail current amplitude did not correlate with the degree of receptor desensitation (Bi) resulting from a 20s 5-HT application, but correlated with 5-HT-induced current density (Bii). Data represent individual recordings.
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Cl-indole does not induce tail currents in the heteromeric 5-HT 3 AB receptor
In contrast to the 5-HT 3 A receptor, the heteromeric 5-HT 3 AB receptor has been reported to have only one orthosteric site, formed at the interface of two A subunits (Miles et al., 2013) . Since the action of Cl-indole requires the presence of the orthosteric agonist, we hypothesized that the agonist activity of Cl-indole would not be apparent at the heteromeric receptor. Unlike the homomeric receptor, the presence of Cl-indole (10 μM) did not induce a tail current after removal of 5-HT; it did however potentiate the peak current amplitude ( Figure 9B ). As subtle differences exist in the pharmacology of the heteromeric receptor, we tested if a higher concentration of Cl-indole (30 μM) would induce tail currents. Cl-indole did not induce a tail current but did again potentiate the peak current amplitude (Figure 9A, B) . Consistent with the lack of tail current in the heteromeric receptor, the presence of submaximal concentrations of 5-HT did not modulate the affinity of Cl-indole binding at the 5-HT 3 AB receptor (Table 2) .
Discussion
Our previous studies demonstrated that Cl-indole was a potent and selective positive allosteric modulator of the 5-HT 3 receptor (Newman et al., 2013) . Cl-indole slowed the rate at which 5-HT 3 A receptor-mediated currents decayed back to baseline following a brief application of 5-HT and appeared able to reactivate desensitized receptors (Newman et al., 2013) . In the present study, we demonstrated that Cl-indole alone fails to activate the 5-HT 3 A receptor, although the presence of 5-HT reveals an action of Cl-indole once desensitization had commenced (Figure 1) . Based on the present and our previous studies, we therefore hypothesized that Clindole may modulate the desensitized state of the receptor. In the present studies, the mechanism of action of Cl-indole was explored more fully. We used prolonged applications of the endogenous orthosteric agonist, 5-HT, to induce robust desensitization of the 5-HT 3 A receptor but Cl-indole did not alter either the rate or magnitude of receptor desensitization (Figure 2Biii ) or the rate at which 5-HT 3 A receptors recovered following desensitization (Figure 3) . Given that some other allosteric modulators of 5-HT 3 A receptors have a profound effect on desensitization rate (Kooyman et al., 1993; Van Hooft et al., 1997; Deiml et al., 2004) , our data suggest that Cl-indole functions via an alternate mechanism.
A surprising observation from the desensitization studies was that the presence of Cl-indole revealed tail currents following removal of the 5-HT. Our unpublished data show that mutation of the 5OHI binding site in the human 5-HT 3 A receptor used in this study had no effect on the ability of Cl-indole to modulate the 5-HT response. A tail current has previously been described following the treatment of mouse 5-HT 3 A receptors with 5OHI (Kooyman et al., 1993) . High concentrations of 5OHI (10 to 50 mM) evoked a tail current superficially similar to that evoked by Cl-indole in our study. However, unlike Cl-indole, high concentrations of 5OHI inhibited the 5-HT response and the tail currents could be ascribed to relief of 5OHI-mediated block. Similarly, 10 mM trichloroethanol also induced a tail current at mouse 5-HT 3 A receptors, which was ascribed to relief from a blocked state (Zhou and Lovinger, 1996) . Indeed, tail currents are most commonly ascribed to the relief from non-competitive open channel block. For example, penicillin is an openchannel blocker at the GABA A receptor, where it binds within the pore and locks the receptor into an open but blocked conformation (Rossokhin et al., 2014) . Removal of penicillin generates large tail-currents as receptors transition from an open-blocked to an open, ion-permeant state (Rossokhin et al., 2014) . Open channel block of the 5-HT 3 A receptor by 5-HT has been described by Hapfelmeier et al. (2003) in macroscopic currents and at the single channel level by Corradi et al. (2009) . It has been proposed that 5-HT can occupy a non-agonist binding site and block conductance through the receptor in an open-channel like manner. It is therefore possible that Cl-indole may enhance 5-HT-mediated open-channel block, thereby causing a larger proportion of receptors to exist in a blocked state during continued agonist exposure. Following agonist removal, this population of receptors would transition from blocked to the openconductive state and produce the observed tail currents. However, our data indicates that Cl-indole does not function
Figure 5
Cl-indole does not modulate the current-voltage relationship of the 5-HT 3 A receptor current. (A) I/V curves (À120 to 120 mV) were constructed at the peak of the Cl-indole-induced tail current. (B) The current voltage relationship was unaltered by Cl-indole (10 μM). Data represent the mean ± SEM, n = 6.
Cryptic orthosteric modulation of 5-HT 3 A BJP in this manner. Previous reports of 5-HT-mediated channel block have shown that it is only evident at concentrations exceeding 5 μM (Hapfelmeier et al., 2003; Corradi et al., 2009) . In the present studies, tail currents were associated with lower concentrations of 5-HT, the amplitude of tail currents was not altered across the range of 5-HT concentrations investigated (1-10 μM), and tail currents were not observed in the absence of Cl-indole. Taken together, these data indicate that Cl-indole-induced tail currents do not arise from promotion of channel block.
We propose that Cl-indole potentiates 5-HT mediated responses by a novel mechanism where in the presence of the orthosteric ligand (5-HT), Cl-indole can bind to orthosteric sites leading to increased receptor activity. Several observations support this hypothesis: (i) the concentrationdependent presence of 5-HT reveals an ability of Cl-indole to compete for the [ 3 H]granisetron-labelled orthosteric binding; (ii) the orthosteric 5-HT 3 receptor antagonist, ondansetron, effectively blocks the Cl-indole-dependent tail current; and (iii) the IV curve of the tail current is indistinguishable from that for the 5-HT 3 A receptor. Additional support is lent by the observation that in a heteromeric 5-HT 3 AB receptor with potentially only one available orthosteric site, no tail current was observed. Our interpretation is therefore that Cl-indole acts as both a positive allosteric modulator and an orthosteric agonist requiring the presence of an orthosteric ligand such as 5-HT.
Ago-allosteric modulators have been defined as ligands that can function both as an agonist in their own right and as an allosteric modulator of the orthosteric ligand (Schwartz and Holst, 2007) . This class of modulators has been well described for GPCRs (Smith et al., 2011a; Smith et al., 2011b; Yamazaki et al., 2012) but has also been described for cys-loop
LGICs. Thus phenobarbitol, 4BP-TQS and thymol and carvacrol have all been described as ago-allosteric modulators for GABA A , nicotinic α7 and 5-HT 3 A receptors, respectively (Amin and Weiss, 1993; Gill et al., 2011; Lansdell et al., 2015) . However, all these modulators act as allosteric agonists in the absence of the orthosteric ligand. Interestingly, 4BP-TQS acts via a site in the TM2 domain of the nicotinic Figure 6 Cl-indole induced tail current amplitude is independent of 5-HT concentration. (A and Bi) In the presence of Cl-indole (10 μM), application of 5-HT evoked a concentration-dependent inward current (trace representative of 9 recordings). (A and Bii) A similar amplitude tail current was observed at all agonist concentrations. (Biii) The rise time of the tail currents was dependent on 5-HT concentration. Bar graphs represent mean + SEM, n = 9; *P< 0.05. α7 receptor (Gill et al., 2011) , while thymol and carvacrol display agonism via a site in TM1 of the 5-HT 3 A receptor (Lansdell et al., 2005) .
The proposed mechanism of action of Cl-Indole shows some similarity to compounds that modulate nAChRs by acting through 'non-canonical' extracellular agonist binding sites (Short et al., 2015) or as 'accessory siteselective agonists' . These compounds act at heteromeric receptors with the mechanism of action explained by compounds interacting with sites distinct from the conventional orthosteric site. Importantly, this study examined the effect of Cl-Indole on homomeric 5-HT 3 A receptors, which are expected to have five identical agonist binding sites.
Therefore, Cl-indole fundamentally differs from previously described modulators by its agonist action at the orthosteric site, as well as its allosteric action, both of which require the additional presence of an orthosteric ligand such as 5-HT. Since the action of Cl-indole is hidden, requiring the presence of an orthosteric agonist to be revealed, we propose that it forms a new class of action that we term cryptic orthosteric modulation.
The 5-HT 3 A receptor has five orthosteric sites (Barnes et al., 2009 ) of which two to three are believed to be occupied for maximal receptor activation (Corradi et al., 2009) . The question therefore arises whether Cl-indole binds to unoccupied orthosteric sites or does it compete with 5-HT for occupied sites? Both in this study and previously (Newman et al., 2013) , we have shown that Cl-indole potentiates responses induced by sub-maximal but not maximal 5-HT concentrations. Studies investigating receptor stoichiometry using nAChR suggest that agonist binding to a single binding site within the LGIC complex can activate the channel (Rayes et al., 2009; Andersen et al., 2013) . As the number of binding sites engaged increases, the channel can become maximally activated (Corradi et al., 2009) . Therefore, at low agonist concentrations, it would be predicted that relatively few binding sites are occupied and the current amplitude is consequently lower. Cl-indole can then interact with the free orthosteric sites to potentiate the response; this action is only revealed Cryptic orthosteric modulation of 5-HT 3 A BJP by the presence of 5-HT. In contrast at higher 5-HT concentrations, multiple orthosteric binding sites are occupied, effectively blocking Cl-indole access to the orthosteric site. As a result Cl-indole cannot potentiate the response. Once the 5-HT molecules begin to dissociate, the orthosteric binding sites become sequentially available, allowing Cl-indole to bind and re-activate the channel, thus generating the evident tail current. This proposes that Cl-indole can only interact with unoccupied orthosteric sites. Our previous study demonstrated that when Cl-indole was applied to desensitized receptors, a current was evoked (Newman et al., 2013) , which in the light of the present findings suggests that this current may have resulted from generation of a tail current.
The heteromeric 5-HT 3 AB receptor has been reported to have the subunit order of A-A-B-A-B (Miles et al., 2013) . Since the orthosteric site is formed from an A-A interface, this stoichiometry suggests the presence of just a single orthosteric site in the heteromeric 5-HT 3 AB receptor. Our hypothesis is that the tail current is due to agonism of the receptor via the orthosteric site in the presence of the orthosteric ligand. This is supported by the absence of a tail current and lack of Cl-indole competition in the presence of 5-HT for theheteromeric 5-HT 3 AB receptor. Interestingly, the peak 5-HT 3 AB heteromeric receptor current was potentiated by Cl-indole. We interpret this to mean that Cl-indole may have an allosteric action via the A-B and B-A interfaces. The potential for allosteric action through an A-B or B-A site is supported by Miles et al. (2015) who showed that mcPBG can be both an agonist and allosteric modulator at the heteromeric receptor. These observations are consistent with our proposal that Cl-indole forms a new class of molecule exhibiting both agonist and allosteric actions requiring the presence of the orthosteric ligand.
The novel mechanism of action of Cl-indole at the 5-HT 3 receptor may offer therapeutic advantages for ligands with this mechanism at LGICs. Thus, for instance, a potentiation of 5-HT 3 receptor function may benefit patients with constipation-predominant irritable bowel syndrome. Furthermore, if the novel mechanism translates to other members of the LGIC receptor superfamily, then such potentiation of GABA A receptors for example may offer benefits for the treatment of a variety of conditions such as anxiety. Alternatively, a potentiation of nAChR may benefit patients with cognitive decline.
Figure 8
The presence of 5-HT allows Cl-indole to compete for [ 3 H]-granisetron binding to the orthosteric site of the 5-HT 3 A receptor. Left graph: Cl-indole (up to 100 μM) essentially does not compete for [ 3 H]-granisetron in the absence of 5-HT, but in the presence of 5-HT (10-300 nM), there is a concentration-dependent increase in the affinity of Cl-indole for the [ 3 H]-granisetron-labelled orthosteric site. Right graph: the same concentrations of 5-HT fail to alter the affinity of the orthosteric agonist, PBG. Data from a single experiment that was representative of four to eight independent experiments (see Table 1 for summary of arising data). In summary, using the 5-HT 3 A receptor as a model, this study identifies a previously unknown mode of activation of
LGICs. We demonstrated that Cl-indole represents a modulator requiring the presence of the orthosteric ligand for its actiona Cryptic Orthosteric Modulator. The retained physiological control via the endogenous agonist to reveal both actions may offer therapeutic advantages for drugs targeting
LGICs via this mechanism.
Figure 9
Cl-indole does not induce tail currents in heteromeric 5-HT 3 AB receptors. (A) Pressure ejection of 5-HT (10 μM, 20 s, 20 ψ) evoked a rapidly desensitizing current in both control and in the presence of 30 μM Cl-indole. Removal of 5-HT did not induce a tail current in either condition. (B) Cl-indole (30 μM, left panel, n = 5; 10 μM right panel, n = 6) potentiated the peak 5-HT current amplitude. Bar graphs represent mean + SEM; *P<0.05. Data represent IC 50 values for the competing drugs in the absence or presence of 5-HT (mean ± SEM, n = 5).
